[{"id":"33062010-2f9f-457a-bb48-293b21b77b51","acronym":"RAGNAR","url":"https://clinicaltrials.gov/study/NCT04083976","created_at":"2021-01-18T19:59:45.508Z","updated_at":"2025-02-25T12:37:25.290Z","phase":"Phase 2","brief_title":"A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations","source_id_and_acronym":"NCT04083976 - RAGNAR","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" FGFR2 • FGFR • TACC3 • TACC2","pipe":" | ","alterations":" FGFR3 mutation • FGFR mutation • FGFR fusion","tags":["FGFR2 • FGFR • TACC3 • TACC2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR3 mutation • FGFR mutation • FGFR fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Balversa (erdafitinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 316","initiation":"Initiation: 11/20/2019","start_date":" 11/20/2019","primary_txt":" Primary completion: 12/04/2023","primary_completion_date":" 12/04/2023","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-24"},{"id":"9c7ac936-fde1-4b07-9296-dad7240ad183","acronym":"","url":"https://clinicaltrials.gov/study/NCT04963153","created_at":"2021-07-15T13:06:11.818Z","updated_at":"2025-02-25T12:28:14.832Z","phase":"Phase 1","brief_title":"Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy","source_id_and_acronym":"NCT04963153","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • FGFR2 • NECTIN4","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • FGFR2 • NECTIN4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Balversa (erdafitinib) • Padcev (enfortumab vedotin-ejfv)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/07/2022","start_date":" 07/07/2022","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-02-24"},{"id":"0fa68358-5ca0-4783-89e5-388a03a0323e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02421185","created_at":"2021-01-18T11:34:41.906Z","updated_at":"2025-02-25T16:58:47.423Z","phase":"Phase 1/2","brief_title":"Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma","source_id_and_acronym":"NCT02421185","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" FGF","pipe":"","alterations":" ","tags":["FGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Balversa (erdafitinib)"],"overall_status":"Completed","enrollment":" Enrollment 53","initiation":"Initiation: 05/25/2015","start_date":" 05/25/2015","primary_txt":" Primary completion: 05/13/2019","primary_completion_date":" 05/13/2019","study_txt":" Completion: 05/16/2019","study_completion_date":" 05/16/2019","last_update_posted":"2025-02-03"},{"id":"25d363db-b73d-42b4-a08a-717568224b15","acronym":"THOR-2","url":"https://clinicaltrials.gov/study/NCT04172675","created_at":"2021-01-18T20:21:16.432Z","updated_at":"2025-02-25T17:00:18.386Z","phase":"Phase 2","brief_title":"A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)","source_id_and_acronym":"NCT04172675 - THOR-2","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" FGFR","pipe":" | ","alterations":" FGFR mutation • FGFR fusion","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR mutation • FGFR fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Balversa (erdafitinib) • mitomycin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 107","initiation":"Initiation: 02/28/2020","start_date":" 02/28/2020","primary_txt":" Primary completion: 07/12/2024","primary_completion_date":" 07/12/2024","study_txt":" Completion: 03/03/2025","study_completion_date":" 03/03/2025","last_update_posted":"2025-02-03"},{"id":"5c6decd8-2f64-40a9-8da2-299c3dfe4465","acronym":"EAY131-K2","url":"https://clinicaltrials.gov/study/NCT06351371","created_at":"2025-02-27T09:37:17.782Z","updated_at":"2025-02-27T09:37:17.782Z","phase":"Phase 2","brief_title":"Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2)","source_id_and_acronym":"NCT06351371 - EAY131-K2","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PIK3CA","pipe":" | ","alterations":" PIK3CA mutation","tags":["PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Balversa (erdafitinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 07/03/2018","start_date":" 07/03/2018","primary_txt":" Primary completion: 06/02/2022","primary_completion_date":" 06/02/2022","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-10-14"},{"id":"af8ba850-b78d-4d55-8fbd-fbea3bc4dd39","acronym":"EAY131-K1","url":"https://clinicaltrials.gov/study/NCT06308822","created_at":"2025-02-27T09:19:29.964Z","updated_at":"2025-02-27T09:19:29.964Z","phase":"Phase 2","brief_title":"Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)","source_id_and_acronym":"NCT06308822 - EAY131-K1","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PIK3CA","pipe":" | ","alterations":" PIK3CA mutation","tags":["PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Balversa (erdafitinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 08/20/2018","start_date":" 08/20/2018","primary_txt":" Primary completion: 07/27/2022","primary_completion_date":" 07/27/2022","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-09-16"},{"id":"a1596462-69b2-4cbb-bcf0-d0bed5de43d8","acronym":"","url":"https://clinicaltrials.gov/study/NCT02508467","created_at":"2021-01-18T12:06:37.223Z","updated_at":"2024-07-02T16:35:09.856Z","phase":"Phase 1","brief_title":"A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma","source_id_and_acronym":"NCT02508467","lead_sponsor":"Blueprint Medicines Corporation","biomarkers":" FGF19","pipe":"","alterations":" ","tags":["FGF19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fisogatinib (BLU-554)"],"overall_status":"Completed","enrollment":" Enrollment 146","initiation":"Initiation: 07/31/2015","start_date":" 07/31/2015","primary_txt":" Primary completion: 06/30/2021","primary_completion_date":" 06/30/2021","study_txt":" Completion: 02/28/2024","study_completion_date":" 02/28/2024","last_update_posted":"2024-04-12"},{"id":"1d4ba0e5-2e91-4eb0-9b78-dcfdf4bea1c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05564416","created_at":"2022-10-03T15:56:45.916Z","updated_at":"2024-07-02T16:35:16.428Z","phase":"Phase 2","brief_title":"Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial","source_id_and_acronym":"NCT05564416","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • FGFR3","pipe":" | ","alterations":" FGFR fusion","tags":["PD-L1 • FGFR3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tecentriq (atezolizumab) • Balversa (erdafitinib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/12/2023","start_date":" 10/12/2023","primary_txt":" Primary completion: 11/03/2023","primary_completion_date":" 11/03/2023","study_txt":" Completion: 11/03/2023","study_completion_date":" 11/03/2023","last_update_posted":"2024-03-05"},{"id":"43d8bb89-a022-4c97-a5c6-8d7b86cf251f","acronym":"BB102-ST-Ⅰ-02","url":"https://clinicaltrials.gov/study/NCT06258408","created_at":"2024-02-14T16:26:56.302Z","updated_at":"2024-07-02T16:35:18.596Z","phase":"Phase 1","brief_title":"A Phase 1 Study of BB102 in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT06258408 - BB102-ST-Ⅰ-02","lead_sponsor":"BrodenBio Co., Ltd.","biomarkers":" FGF19 • FGFR4","pipe":"","alterations":" ","tags":["FGF19 • FGFR4"],"overall_status":"Recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 12/29/2022","start_date":" 12/29/2022","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-02-20"},{"id":"45391173-bfa1-492f-828d-d0cb5112e61f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03238196","created_at":"2021-01-17T17:26:50.151Z","updated_at":"2024-07-02T16:35:21.276Z","phase":"Phase 1","brief_title":"Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer","source_id_and_acronym":"NCT03238196","lead_sponsor":"Vanderbilt-Ingram Cancer Center","biomarkers":" HER-2 • ER • FGFR2 • FGFR1 • FGFR4 • FGF23","pipe":" | ","alterations":" HER-2 negative • FGFR1 amplification • FGFR3 amplification • FGFR4 amplification • FGFR amplification","tags":["HER-2 • ER • FGFR2 • FGFR1 • FGFR4 • FGF23"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • FGFR1 amplification • FGFR3 amplification • FGFR4 amplification • FGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Balversa (erdafitinib) • fulvestrant"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 08/18/2017","start_date":" 08/18/2017","primary_txt":" Primary completion: 04/30/2021","primary_completion_date":" 04/30/2021","study_txt":" Completion: 09/25/2024","study_completion_date":" 09/25/2024","last_update_posted":"2024-02-01"},{"id":"7ca1a5b6-b5e3-4622-8a4f-a462e3ff4894","acronym":"","url":"https://clinicaltrials.gov/study/NCT05498519","created_at":"2022-08-13T17:57:29.618Z","updated_at":"2024-07-02T16:35:48.307Z","phase":"Phase 1","brief_title":"A First-in-Human, Phase 1 Study of SY-4798 in Patients With Advanced Solid Tumor","source_id_and_acronym":"NCT05498519","lead_sponsor":"Shouyao Holdings (Beijing) Co. LTD","biomarkers":" FGF19","pipe":"","alterations":" ","tags":["FGF19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SY-4798"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 04/15/2021","start_date":" 04/15/2021","primary_txt":" Primary completion: 04/15/2024","primary_completion_date":" 04/15/2024","study_txt":" Completion: 04/15/2024","study_completion_date":" 04/15/2024","last_update_posted":"2023-05-11"},{"id":"8618c3fa-4468-4945-aa54-0b000144497e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04194801","created_at":"2023-02-06T18:00:21.094Z","updated_at":"2024-07-02T16:35:56.405Z","phase":"Phase 1/2","brief_title":"A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma","source_id_and_acronym":"NCT04194801","lead_sponsor":"CStone Pharmaceuticals","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cejemly (sugemalimab) • fisogatinib (BLU-554)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 12/16/2019","start_date":" 12/16/2019","primary_txt":" Primary completion: 10/20/2021","primary_completion_date":" 10/20/2021","study_txt":" Completion: 10/20/2021","study_completion_date":" 10/20/2021","last_update_posted":"2023-02-06"},{"id":"6e723a13-4912-4048-8073-6e3f7a645994","acronym":"","url":"https://clinicaltrials.gov/study/NCT05441475","created_at":"2022-09-26T15:56:05.332Z","updated_at":"2024-07-02T16:36:03.502Z","phase":"Phase 2","brief_title":"A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab in HCC Patients","source_id_and_acronym":"NCT05441475","lead_sponsor":"Abbisko Therapeutics Co, Ltd","biomarkers":" FGF19","pipe":" | ","alterations":" FGF19 overexpression","tags":["FGF19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGF19 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • irpagratinib (ABSK011)"],"overall_status":"Recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 12/30/2021","start_date":" 12/30/2021","primary_txt":" Primary completion: 07/20/2024","primary_completion_date":" 07/20/2024","study_txt":" Completion: 10/10/2024","study_completion_date":" 10/10/2024","last_update_posted":"2022-09-26"},{"id":"aba6b3e5-cb1f-46a6-86b7-19b8fd3e71e7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04906434","created_at":"2021-05-28T13:52:37.440Z","updated_at":"2024-07-02T16:36:08.012Z","phase":"Phase 1","brief_title":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor","source_id_and_acronym":"NCT04906434","lead_sponsor":"Abbisko Therapeutics Co, Ltd","biomarkers":" FGF19","pipe":" | ","alterations":" FGF19 overexpression","tags":["FGF19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGF19 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irpagratinib (ABSK011)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 02/26/2020","start_date":" 02/26/2020","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2022-06-30"},{"id":"a2c2a881-d186-4a3f-be02-3a38da1848d0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04699643","created_at":"2021-01-19T20:50:12.745Z","updated_at":"2024-07-02T16:36:36.469Z","phase":"Phase 1/2","brief_title":"FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04699643","lead_sponsor":"EverNov Medicines (Zhuhai Hengqin) Co., Ltd","biomarkers":" FGF19","pipe":" | ","alterations":" FGF19 positive • FGF19 expression","tags":["FGF19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGF19 positive • FGF19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • roblitinib (FGF401)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 07/30/2020","start_date":" 07/30/2020","primary_txt":" Primary completion: 06/01/2023","primary_completion_date":" 06/01/2023","study_txt":" Completion: 06/01/2023","study_completion_date":" 06/01/2023","last_update_posted":"2021-01-07"},{"id":"bad33fae-f9c7-474e-879f-6eabe449864a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02038673","created_at":"2021-01-18T09:21:26.925Z","updated_at":"2024-07-02T16:37:05.880Z","phase":"Phase 1","brief_title":"An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors","source_id_and_acronym":"NCT02038673","lead_sponsor":"Astellas Pharma Inc","biomarkers":" FGF19 • FGF23","pipe":"","alterations":" ","tags":["FGF19 • FGF23"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ASP5878"],"overall_status":"Completed","enrollment":" Enrollment 86","initiation":"Initiation: 11/05/2013","start_date":" 11/05/2013","primary_txt":" Primary completion: 07/19/2017","primary_completion_date":" 07/19/2017","study_txt":" Completion: 07/19/2017","study_completion_date":" 07/19/2017","last_update_posted":"2018-10-22"}]